Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313637 · ClinicalTrials.gov registry record · Phase 3
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,493
- Enrollment target
- 20
- Study locations
NCT01313637 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,493 participants, above the 1,024-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT01313637, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,493 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).
Conditions Studied
Interventions
- DRUG GW642444 25mcg
- DRUG GSK573719/GW642444 125/25mcg
- DRUG GSK573719 125mcg
- DRUG Placebo only
Study Locations (20)
California
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Palo Alto
- GSK Investigational Site - Riverside
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - Torrance
Florida
- GSK Investigational Site - Clearwater
- GSK Investigational Site - DeLand
- GSK Investigational Site - Orlando
- GSK Investigational Site - Panama City
Alabama
- GSK Investigational Site - Jasper
Arizona
- GSK Investigational Site - Phoenix
Kansas
- GSK Investigational Site - Topeka
Michigan
- GSK Investigational Site - Livonia
Minnesota
- GSK Investigational Site - Plymouth
Nebraska
- GSK Investigational Site - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,493 participants |
| Start Date | 2011-03-01 |
| Est. Completion | 2012-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313637
The ClinicalTrials.gov registry entry for NCT01313637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,493 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,024-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (46% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 4 interventions - of which GW642444 25mcg is the first listed.
NCT01313637 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01313637 about?
NCT01313637 is a clinical study titled "A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD". This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inh...
What is the current status of trial NCT01313637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,493 participants. The study started on 2011-03-01. Estimated completion is 2012-04-19.
What conditions does trial NCT01313637 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT01313637?
The interventions under investigation include: GW642444 25mcg (DRUG), GSK573719/GW642444 125/25mcg (DRUG), GSK573719 125mcg (DRUG), Placebo only (DRUG).
Who is sponsoring clinical trial NCT01313637?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01313637 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.